These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The impact of hepatitis B virus infected patients or donors on the outcome of hematopoietic stem cell transplantation].
    Author: Feng S, Han M, Zhang L, Li C, Qiu L, Li H, Wang Z, Jiang R, Yan W, Han Z.
    Journal: Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):414-6. PubMed ID: 11877014.
    Abstract:
    OBJECTIVE: To investigate the impact of recipients and/or donors infected with hepatitis B on the outcome of hematopoietic stem cells transplantation (HSCT). METHODS: We analyzed retrospectively the transplantation outcome in 26 of 164 hematological diseases patients who and whose donors were infected with hepatitis prior to transplantation. RESULTS: (1) Three of the 26 patients developed VOD after HSCT, the incidence (11.5%) is significant higher than that in patients and donors who did not infected with HBV (P < 0.05). (2) Two of 5 patients transfused hematopoietic stem cells from HBsAg + donors developed hepatitis B. (3) Four patients with allogeneic stem cell transplantation developed hepatic failure (HF) which occurred during cyclosporin (CsA) being tapered off or withdrawal. The incidence of HF in patients and/or donors infected with HBV (15.4%) is obviously higher than that in patients and donors who did not (0.08%, P < 0.01). (4) In 4 patients with HbeAg +, 2 patients died of HF after allogeneic HSCT, the other 2 patients survived after autologous HSCT. CONCLUSION: Donors and recipients infected with hepatitis B are not contraindication of HSCT, but patients with allogeneic HSCT are in danger to develop LF during CsA being tapered off or withdrawal.
    [Abstract] [Full Text] [Related] [New Search]